Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sapporo Clinical Laboratory (TSE:9776) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Sapporo Clinical Laboratory 5-Year Yield-on-Cost % Related Terms
Sapporo Clinical Laboratory 5-Year Yield-on-Cost % Competitor Comparison
For the Pharmaceutical Retailers subindustry, Sapporo Clinical Laboratory's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sapporo Clinical Laboratory 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sapporo Clinical Laboratory's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Sapporo Clinical Laboratory's 5-Year Yield-on-Cost % falls into.
Sapporo Clinical Laboratory 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Sapporo Clinical Laboratory (TSE:9776) has a 5-Year Yield-on-Cost % of 1.18 as of Aug. 23, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sapporo Clinical Laboratory and its competitors. This is near median its historical median of 1.08. Over the past decade, Sapporo Clinical Laboratory's 5-Year Yield-on-Cost % has ranged from 0.79 to 1.18.
Is Sapporo Clinical Laboratory's 5-Year Yield-on-Cost % too high?
Sapporo Clinical Laboratory's current 5-Year Yield-on-Cost % of 1.18 is near median its 10-year median of 1.08. Over the past 10 years, this metric has ranged from a low of 0.79 to a high of 1.18. The Healthcare Providers & Services industry median 5-Year Yield-on-Cost % is 2.97. Sapporo Clinical Laboratory's value of 1.18 is 60.2% below this industry median. Overall, Sapporo Clinical Laboratory has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Sapporo Clinical Laboratory's 5-Year Yield-on-Cost % compare to competitors?
Sapporo Clinical Laboratory's 5-Year Yield-on-Cost % of 1.18 can be compared against companies in the Healthcare Providers & Services industry. The industry median 5-Year Yield-on-Cost % is 2.97. Sapporo Clinical Laboratory's value of 1.18 is 60.2% below this benchmark. Historically, Sapporo Clinical Laboratory's own 5-Year Yield-on-Cost % has ranged from 0.79 to 1.18 over the past decade. While the company's 10-year median is 1.08 vs. the industry median of 2.97, Sapporo Clinical Laboratory has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 2.97, based on 278 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sapporo Clinical Laboratory's current 5-Year Yield-on-Cost % of 1.18 is 60.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sapporo Clinical Laboratory and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sapporo Clinical Laboratory's current 5-Year Yield-on-Cost % is 1.18, which is near median its own 10-year median of 1.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sapporo Clinical Laboratory stock overvalued right now?
Sapporo Clinical Laboratory (TSE:9776) has a current 5-Year Yield-on-Cost % of 1.18. The stock's GF Value™ is 円1,041.47, compared to a current price of 円1,960.00 — trading 88.2% above its estimated fair value. The current 5-Year Yield-on-Cost % is 1.18, which is near median its 10-year median of 1.08 and 60.2% below the Healthcare Providers & Services industry median of 2.97. Sapporo Clinical Laboratory's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Sapporo Clinical Laboratory (TSE:9776), the current 5-Year Yield-on-Cost % is 1.18 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sapporo Clinical Laboratory (TSE:9776) Overvalued in 2026?
Based on GuruFocus' analysis, Sapporo Clinical Laboratory stock appears to be overvalued.
The current stock price of 円1,960.00 is trading 88.2% above its estimated GF Value™ of 円1,041.47.
Key valuation signals for TSE:9776:
5-Year Yield-on-Cost %: 1.18 (near median its 10-year median of 1.08)
GF Value™: 円1,041.47 vs. price of 円1,960.00 (88.2% above fair value)
Industry Position: 60.2% below the Healthcare Providers & Services median
No single metric tells the full story. See the TSE:9776 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sapporo Clinical Laboratory Inc. is a Japan based company engaged in offering clinical testing services. Its portfolio of services covers clinical examination, pathological examination, dispensing pharmacy, food hygiene environmental test, and radiation management. It is also engaged in the development of an integrated system for clinical testing.
43GF Score
Get the complete analysis for TSE:9776
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:9776 has been successfully added to your 
